108 related articles for article (PubMed ID: 17523751)
1. Estimation, power and sample size calculations for stochastic cost and effectiveness analysis.
Walter SD; Gafni A; Birch S
Pharmacoeconomics; 2007; 25(6):455-66. PubMed ID: 17523751
[TBL] [Abstract][Full Text] [Related]
2. Use of confidence intervals and sample size calculations in health economic studies.
Sacristán JA; Day SJ; Navarro O; Ramos J; Hernández JM
Ann Pharmacother; 1995; 29(7-8):719-25. PubMed ID: 8520090
[TBL] [Abstract][Full Text] [Related]
3. Power and sample size calculations for stochastic cost-effectiveness analysis.
Briggs AH; Gray AM
Med Decis Making; 1998; 18(2 Suppl):S81-92. PubMed ID: 9566469
[TBL] [Abstract][Full Text] [Related]
4. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data.
Willan AR; O'Brien BJ
Health Econ; 1999 May; 8(3):203-11. PubMed ID: 10348415
[TBL] [Abstract][Full Text] [Related]
5. A new approach for sample size calculation in cost-effectiveness studies based on value of information.
Bader C; Cossin S; Maillard A; Bénard A
BMC Med Res Methodol; 2018 Oct; 18(1):113. PubMed ID: 30348087
[TBL] [Abstract][Full Text] [Related]
6. An opportunity cost approach to sample size calculation in cost-effectiveness analysis.
Gafni A; Walter SD; Birch S; Sendi P
Health Econ; 2008 Jan; 17(1):99-107. PubMed ID: 17497751
[TBL] [Abstract][Full Text] [Related]
7. A study on confidence intervals for incremental cost-effectiveness ratios.
Wang H; Zhao H
Biom J; 2008 Aug; 50(4):505-14. PubMed ID: 18663759
[TBL] [Abstract][Full Text] [Related]
8. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane.
Briggs A; Fenn P
Health Econ; 1998 Dec; 7(8):723-40. PubMed ID: 9890333
[TBL] [Abstract][Full Text] [Related]
9. Power and sample assessments for tests of hypotheses on cost-effectiveness ratios.
Gardiner JC; Huebner M; Jetton J; Bradley CJ
Health Econ; 2000 Apr; 9(3):227-34. PubMed ID: 10790701
[TBL] [Abstract][Full Text] [Related]
10. Bootstrap analyses of cost effectiveness in antidepressant pharmacotherapy.
Obenchain RL; Melfi CA; Croghan TW; Buesching DP
Pharmacoeconomics; 1997 May; 11(5):464-72. PubMed ID: 10168034
[TBL] [Abstract][Full Text] [Related]
11. Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation.
Briggs AH; Mooney CZ; Wonderling DE
Stat Med; 1999 Dec; 18(23):3245-62. PubMed ID: 10602149
[TBL] [Abstract][Full Text] [Related]
12. Information created to evade reality (ICER): things we should not look to for answers.
Birch S; Gafni A
Pharmacoeconomics; 2006; 24(11):1121-31. PubMed ID: 17067196
[TBL] [Abstract][Full Text] [Related]
13. The (near) equivalence of cost-effectiveness and cost-benefit analyses. Fact or fallacy?
Donaldson C
Pharmacoeconomics; 1998 Apr; 13(4):389-96. PubMed ID: 10178663
[TBL] [Abstract][Full Text] [Related]
14. Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.
Zethraeus N; Johannesson M; Jönsson B; Löthgren M; Tambour M
Pharmacoeconomics; 2003; 21(1):39-48. PubMed ID: 12484802
[TBL] [Abstract][Full Text] [Related]
15. Average cost-effectiveness ratio with censored data.
Bang H; Zhao H
J Biopharm Stat; 2012; 22(2):401-15. PubMed ID: 22251182
[TBL] [Abstract][Full Text] [Related]
16. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem.
Willan AR; O'Brien BJ
Health Econ; 1996; 5(4):297-305. PubMed ID: 8880166
[TBL] [Abstract][Full Text] [Related]
17. Estimating incremental cost-effectiveness ratios and their confidence intervals with differentially censored data.
Wang H; Zhao H
Biometrics; 2006 Jun; 62(2):570-5. PubMed ID: 16918922
[TBL] [Abstract][Full Text] [Related]
18. Power and sample size calculation for incremental net benefit in cost effectiveness analyses with applications to trials conducted by the Canadian Cancer Trials Group.
Everest L; Chen BE; Hay AE; Cheung MC; Chan KKW
BMC Med Res Methodol; 2023 Aug; 23(1):179. PubMed ID: 37537545
[TBL] [Abstract][Full Text] [Related]
19. [Methods for analyzing uncertainty].
Ferriols R; Alós M
Farm Hosp; 2011 May; 35 Suppl 2():3-9. PubMed ID: 22445503
[TBL] [Abstract][Full Text] [Related]
20. Statistical analysis in pharmacoeconomic studies. A review of current issues and standards.
Coyle D
Pharmacoeconomics; 1996 Jun; 9(6):506-16. PubMed ID: 10160478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
